Lilly Endowment sells $137 million in Eli Lilly shares…
After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.…
Eli Lilly (LLY) plans to invest more than $1B in India in the coming years to boost manufacturing and supply…
LLY shares have jumped 16% last week as Pfizers landmark government deal boosted investor confidence across the pharma sector.…
Eli Lilly is riding a big trend.…
Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through…
Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.…
Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.…
Pfizers deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.…
In the past week, a U.S. federal judge dismissed Eli Lillys lawsuit against Willow Health, a telehealth competitor to Hims…
Market Analysis by covering: Eli Lilly and Company, Merck & Company Inc, Pfizer Inc, AbbVie Inc. Read s Market…
What Happened? A number of stocks jumped in the afternoon session after news of a new government prescription drug policy…
Eli Lilly was asked to produce more insulin; Pfizer to produce more of its top-selling cancer drug Ibrance and its…
Here are the stocks that made the biggest moves today.…
Eli Lilly, Merck Lead Market Cap Stock Movers on Wednesday…
Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizers deal with the Trump administration could lead to more with other firms.…
Earlier this year, Eli Lilly had initiated a lawsuit against Willow Health along with three other telehealth companies concerning the…
…
The pharmaceutical company had a clinical setback earlier this year, but thats now in the rearview mirror.…
Eli Lilly secures EU approval for Alzheimers drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.…
…
Bloomberg journalists discuss todays biggest winners and losers in the stock market. Listen for analysis on the companies making news…
Eli Lillys diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity…
In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the…
More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries…
Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC…
Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.…
…
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according…
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling…
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…
The FDAs warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss…
Eli Lillys orforglipron beat NVOs Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.…
HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat Eli Lilly von "Buy" auf "Hold" abgestuft…
Die Aktie von Eli Lilly (NYSE: LLY) legte am Dienstag deutlich zu und gewann im Tagesverlauf bis zu 5,9 %. Auslöser war die…
Nach der Veröffentlichung enttäuschender Studiendaten erholt sich die Aktie von Eli Lilly langsam wieder. Die neue Abnehmpille Orforglipron von Eli…
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive…
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…
A new, late-stage clinical study shows disappointing results for Eli Lillys weight loss pill Orforglipron. The experimental drug has less…
Shares of rival Novo Nordisk rose as both companies develop weight loss pills.…
Here are some of the stocks posting the biggest moves in midday trading.…
Here are some of the stocks posting the biggest moves in midday trading.…
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to…
These are the stocks posting the largest moves in premarket trading.…
Eli Lillys pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…
…
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight…
Eli Lilly hat neue Studienergebnisse zum oralen GLP?1-Kandidaten Orforglipron vorgelegt. In einer Phase?III-Studie verloren übergewichtige Teilnehmer ohne Diabetes innerhalb von…